2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5919 CAR-T cells in newly diagnosed high-risk large B cell lymphoma

Mingming Zhang, PhD, Jingjing Feng2, Lianxuan Liu, BS3, Shan Fu4, Ruimin Hong5, Houli Zhao6, Pingnan Xiao7, Xin Guo8, Alex H. Zhang, Dr.9, Yongxian HU, MD10, He Huang, MD, PhD11
1 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 Shanghai YaKe Biotechnology Ltd, Shanghai, China
10 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background Standard immunochemotherapy yields suboptimal outcomes in patients with newly diagnosed high-risk large B-cell lymphoma (LBCL). The ZUMA-12 trial demonstrated the feasibility of CD19 chimeric antigen receptor (CAR) T-cell therapy as a first-line treatment, yet more data are needed to support its broader application in this setting. Furthermore, how to design better integrated strategies to further enhance the efficacy and safety of frontline CAR T-cell therapy remains an open question.

Methods In this single-center phase II trial, we enrolled patients with newly diagnosed high-risk LBCL. Patients received two cycles of rituximab, lenalidomide, and Zanubrutinib (ZR2), followed by CD19 CAR T-cell infusion. The primary endpoint was complete response (CR) rate after CAR T-cell therapy.

Results A total of 43 patients were enrolled (median age, 69 years; 44% ≥70). After ZR2 debulking, the overall response rate was 92.9%, with a CR rate of 33.3%. Among the 40 patients who received CAR T-cell therapy, the primary endpoint was met, with a CR rate of 97.5% (95% CI: 86.8%-99.9%). At a median follow-up of 25.6 months, estimated 2-year progression-free survival and overall survival were 84% and 97.6%, respectively. Cytokine release syndrome occurred in 25% of patients (grade 3 in 2.5%); no neurotoxicity or treatment-related deaths occurred.

Conclusions In this phase II trial, ZR2 debulking followed by sequential CD19 CAR T-cell therapy resulted in a high CR rate, durable responses, and a favorable safety profile in patients with newly diagnosed high-risk LBCL. Larger randomized trials are warranted. (ClinicalTrials.gov number, NCT04661020.)

Mingming Zhang, PhD: No relevant conflicts of interest to declare.